Skip to main content
. 2012 Nov 27;10(1):106–110. doi: 10.1007/s13311-012-0156-3

Table 2.

Most Frequent Adverse Events Recorded in 2 Pivotal, Phase III Clinical Trials*

Most Frequent AEs Goodman, et al. (2009) [6] Goodman, et al. (2010) [7]
Urinary tract infection 14 % 17.5 %
Fall 16 % 11.7 %
Insomnia 8 % 10 %
Headache 6 % 9.2 %
Dizziness 8 % 8.3 %
Nausea 6 % 8.3 %
Asthenia 6 % 8.3 %
Upper respiratory infection 6 % 5.8 %
Back pain 6 % 5.8 %
Balance disorder 6 % 5.8 %

*[6, 7]